Summary.-A comparison was made between the cells responsible for demonstrable activity against MSV antigens, using both in vivo and in vitro assays. Similar cells (in terms of size and sensitivity to anti-theta serum) were detected in both assays. However, while lymphoid cells from animals at all stages post-MSV infection were active in protecting irradiated mice from the lethal effect of induction of MSV sarcomata, cells from animals at early stages post-MSV infection (when the tumour was in a progressive phase of growth) were not active in the in vitro assay. By manipulation of the in vivo assay conditions a situation was observed in which cells from " progressor animals " were able to suppress both the in vitro and in vivo activity of regressor lymphoid cells. The potential physiological role of this cell type is discussed.
PREVIOUS papers in this series
, and work from other laboratories (Fefer et al., 1968; Hellstr6m and Hellstrom, 1969; Lamon et al., 1972; Owen and Seeger, 1973) have established that a correlation exists between the ability to detect, in various in vitro assays, cell mediated immunity to murine sarcoma virus (MSV) induced sarcomata and the status of tumour growth in the host animal. While the tumour is in a regressing phase, or after tumour regression, cells can be detected which are capable of killing MSV tumour cells, or recognizing antigens expressed by those cells and then reacting in other immunological tests. In these latter assays (Gorczynski, 1 974b, c; Halliday, 1972 ) the reactive cells are T lymphocytes. When the tumour is in a progressive phase of growth such effector cells are detected less readily. Indeed, there is evidence that serum factors exist at this time in progressor animals which can block the in vitro assays of cell mediated immunity Hellstrom, 1969, 1970; Halliday, 1972) . It has also been reported that such " progressor animals " have in their spleen and lymph node organs a cell type capable of suppressing even the nonspecific T lymphocyte response to the mitogen phytohaemagglutinin, PHA (Gorczynski, 1974c) .
Despite the attention paid to developing in vitro techniques for studying tumour immunity in animal systems, little is known from direct studies of the relative importance of the cells so detected, to the in vivo growth of the tumour. In the MSV system it has been reported that sublethally irradiated mice inoculated with MSV die from the progressive tumour growth unless they are also inoculated with immune cells or serum from regressor animals. Subsequent work suggested that the cells active in such adoptive transfer systems were T lymphocytes (Gorczynski, 1974a; Fefer, 1969) . It was thus of great * To whom all correspondence should be addressed. interest to examine whether these cells were related to the cells detected with in vitro techniques. In addition, we wondered whether cells capable of suppressing in vitro immunity might also be capable of suppressing activity in this in vivo protection assay.
The data presented below suggest that the in vitro assays analysed in earlier reports probably do indeed detect T lymphocytes of relevance to the in vivo growth pattern of the tumour. Some evidence is presented to suggest that the blocking seen in vitro (Gorczynski, 1974c) may play a physiological role in allowing tumour growth in vivo.
MATERIALS AND METHODS
Mice.-Male BALB/C mice from the ICRF breeding unit at Mill Hill were used throughout.
Tumours.-Sarcomata were induced in 3-4 week old BALB/C mice by injection of 0-1 ml of an MSV tumour homogenate into the thigh. The tumour in the mice normally appears at 7 days, progresses to 12 days and then begins to regress, disappearing completely by 21 days (Fefer et al., 1968) . Mice at 9-12 days post-MSV are referred to as progressors, and 18 days and upwards post MSV as regressors.
Irradiation of mice.-Mice were given 700 rad of x-irradiation from a 60Co source at a dose rate of 24 rad/min. All such mice were used at 6 weeks of age and all received 5 x 105 bone marrow cells injected intravenously immediately after irradiation to protect the animals from the potentially lethal effect of bone marrow aplasia. All subsequent virus and cell inoculation into these animals was performed within 3 h of irradiation.
Measurement of tumour volumes.-The dimensions of the developing tumours were measured at different times and tumour volumes calculated from the formula Volume: 0-4 (ab)2, where "a" is the maximum diameter of the tumour, and "b is the diameter at right angles to " a" (Attia, De Ome and Weiss, 1965) .
Cell preparation.-Spleen cells were prepared by teasing the respective tissues apart in ice-cold phosphate buffered saline (PBS).
Large fragments were allowed to settle out and the suspension was centrifuged at 200 g for 10 min at 4°C. Red cells in the spleen preparations were lysed according to the method of Boyle (1968) , using Tris buffered ammonium chloride. Before inoculation of cells into animals, the cells were suspended in PBS with 0-1% bovine serum albumin (BSA). Before assaying in vitro (see below), cells were suspended in MEM leucine-free medium, supplemented with glutamine, nonessential animo acids, and penicillin and streptomycin. All cell counts referred to below are viable cell counts (determined by trypan blue dye exclusion) unless otherwise stated.
Stimulation of protein synthesis.-The essential features of this assay are described in detail elsewhere (Rosenberg et al., 1972; Gorezynski and Rittenberg, 1974) .
In all of the experiments described herein, where immunity to MSV antigens was investigated in vitro, the antigen preparation used in the in vitro test was a sample of disrupted whole MSV virus, a kind gift from Dr R. A. Knight. This has been characterized in terms of its ability to stimulate MSV-immune lymphoid cells in earlier publications (Gorczynski, 1974b, c) . The final concentration of MSV antigen used in the test was 1-0 mg/ml. The final data from these assays are routinely expressed as a percent stimulation (with 95% confidence limits) of protein synthesis in the presence of antigen (compared with the degree of synthesis in the absence of antigen). All groups (with and without antigen) were set up in triplicate.
Velocity cell sedimentation.-Velocity cell sedimentation was performed as described previously (Miller and Phillips, 1969) . A sterile glass sedimentation chamber, 11-0 cm in diameter, was used throughout. Cells were loaded in 0.3% BSA in PBS; a 0.6-2.0% BSA in PBS buffered step gradient was used. All separations were performed for 3 h at 4°C.
Antisera and treatment of cells with antisera.-The preparation and testing of a heterologous rabbit anti-mouse brain associated theta antigen (Br anti 0) and an antimouse immunoglobulin (anti-Ig) are described in detail elsewhere (Gorczynski, 1974a) .
By the criteria described in this communication, the Br anti-6 was a functional anti-T cell reagent, and the anti-Ig an anti-B cell reagent. Cells to be treated with either antiserum and/or complement were suspended to a final concentration (in serum or complement) of 10 x 106 cells/ml. The antisera and complement were diluted for use in PBS with 0-1% BSA. Br anti-0 was used at a final concentration of 1/15 and anti-Ig at a final concentration of 1/10. Cells were incubated in antiserum for 90 min at 40C, centrifuged at 200 g for 5 min at 40C and resuspended in guinea-pig complement (diluted 1/10 in PBS with 0-1% BSA). The cells were incubated for 45 min at 370C in a humidified CO2 containing atmosphere and then washed twice as above. The final cell pellet was resuspended in the medium appropriate for the test required and anlysed as described in the text. Typical data to demonstrate the specificity of the two antisera are shown in Table I .
RESULTS
Correlation of anti-MS V activity in vitro with ability to protect sublethally irradiated
MS V inoculated mnice
Earlier publications have shown that cells from MSV regressor animals can be stimulated to enhanced protein synthesis in vitro by MSV antigens, and can also protect sublethally irradiated MSV inoculated mice from the lethal effects of progressive tumour growth (Gorezynski, 1974a, b) . In contrast, it was shown that spleen cells taken from MSV progressor mice were unable to respond in the in vitro assay used without prior manipulation to remove a cell population which nonspecifically suppressed T cell responses in the spleens of those animals (Gorczynski, 1974c) . In a preliminary examination of the correlation between in vitro and in vivo assays for immunity in this system, we investigated whether there was any difference in the relative abilities of spleen cells taken from mice at different times post MSV to respond in the two assays described.
Mice 24-27 days old were singly injected with MSV at weekly intervals over a period of several weeks. Four mice (given MSV 31, 24, 17 and 10 days earlier) from each group were sacrificed, together with 4 non-infected mice (whose age was approximately a mean of that of the other experimental mice), and the spleens within each group were pooled and used to make single cell suspensions. Aliquots of each suspension were assayed in vitro for their ability to be stimulated by MSV antigens. In addition, 10 x 106 cells of each type were given intraperitoneally in 0-5 ml PBS (with BSA) to 6-week old mice which had been irradiated and inoculated with MSV. Two control groups consisted of irradiated mice not given MSV, and irradiated mice given MSV and no spleen cells. Six mice were used for each group and the animals were examined daily for tumour growth and mortality. The data for this experiment are shown in Table II 49±21 ± ± ± ± -I-± 0/6 6/6 6/6 6/6 6/6 6/6 6/6 11(2-4) 11(2 * 3) 12(1. 9) 1 1(1 * 9) 11(1 *8) 11(2 * 0) 16 18 17 17 6/6 0/6 0/6 5/6 6/6 6/6 6/6 (a) Cells were pooled from 4 animals for each group as described in the text. For the in vitro test 4 x 106 cells were cultured in glass tubes, with or without MSV antigen. For the in vivo test 10 x 106 cells were inoculated intraperitoneally into sublethally irradiated mice previously injected as described under (c).
(b) Arithmetic mean, with 95% confidence limits, using 3 cultures per group.
(c) All mice were 6 weeks of age, irradiated with 700 rad and injected with 5 x 105 adult bone marrow cells. MSV was also inoculated into the groups shown; 6 mice were used per group.
(d) Number of mice developing palpable tumours at some time after MSV inoculation compared with number of mice per group. (e) Day when the mean tumour volume (arithmetic mean) in the group was greatest. The mean tumour volume on this day is shown in brackets.
(f) Day when more than 50% of the mice in the group had no palpable tumours.
(g) Number of mice alive, compared with the number injected at the day shown.
vitro assay. In contrast, cells from all ages of regressor animals seemed fully capable of responding. In comparison with the in vitro data, markedly different results were obtained when the in vivo test was used. It was apparent that animals at all stages were equally active in protecting the irradiated MSV injected mice. No difference was subsequently found even when cells taken from animals at different times post MSV were titrated for their effectiveness in protection (Gorczynski, unpublished data There are several features worthy of note in this Fig. With regard to the protein synthesis data, once again it was seen that unfractionated normal or progressor spleen cells were unresponsive, whereas regressor cells were fully responsive in this test (Gorczynski, 1974b, c) . However, fractionated progressor spleen cells did show activity, unlike fractionated normal spleen cells (Gorczynski, 1974c) . There was a general tendency for activity at early times post MSV to be expressed in both large and small cells, whereas at later times activity in large cells declined. The in vivo protection data seemed to explain the anomaly of Table II . Again, when unfractionated cells were compared, it seemed that progressor and regressor cells were equally active and that there was no good correlation with the in vitro assay. However, upon fractionation, it was apparent that the cell populations active in these two assays in fact cosedimented. While this does not give absolute proof of identity, it does suggest that the reason for the anomaly referred to above may have more to do with the failure of suppression on adoptive transfer of progressor cells, rather than a difference in the effector cell types involved in the two assays. We also observed some slight protection with fractionated normal spleen cells in vivo (panel a). This has been referred to elsewhere (Gorczynski, 1974a; Fefer, 1969) , and is probably due to normal T lymphocytes. In keeping with this suggestion, the sedimentation characteristics of the cells in the normal spleen cell population capable of protection, correlated well with these reported for normal T lymphocytes (Miller and Phillips, 1970) .
Effect of Br anti-6 on protection afforded by regressor cells of different sizes
In an earlier report it was shown that the cells in both normal and MSV regressor animals which could protect irradiated MSV inoculated mice, were sensitive to Br anti-& serum and complement, and were insensitive to anti-Ig serum and complement (Gorczynski, 1 974a) . This characteristic was also reported for those cells capable of in vitro stimulation by MSV antigens (Gorczynski, 1 974b, c>. Data presented in these reports and in the Fig. indicate that after velocity sedimentation activity in both in vitro and in vivo assays is greatly enriched in the large cell region of the gradient. Thus (see Fig.) while the total activity profiles show a relatively equal distribution of activity between slow and fast sedimenting cells, the activity on a per cell basis is increased in the faster sedimenting cells (since there are so few of these cells relative to the numbers of small cells). In view of the limitations in the sensitivities of the two assays used, analysis of unfractionated cells would probably not be fully informative with regard to the properties of fractionated cells. In particular, if, say, 50% of the activity in large cells (which themselves contribute a maximum of 50% of the total activity of unfractionated cells) were insensitive to Br anti-0 serum and complement, it is unlikely that either of the assays used would detect as significant the expected survival (25%) of the activity in unfractionated cells after such antiserum treatment. Accordingly, we investigated the relative sensitivities to Br anti-C serum of the activity of fractionated and unfractionated regressor spleen cells, using both in vivo and in vitro assays. 5 x 108 spleen cells from a pool of 6 mice given MSV 20 days before, were sedimented for 3 h at 4°C, as described in the Materials and Methods section. Cells sedimenting in the regions 2-8-4 1 mm/h (small cells) and 5-8-7-5 mm/h (large cells) were pooled and centrifuged at 200 g for 10 min at 4°C. The populations were resuspended in 5 ml PBS in 0-1% BSA and the viable cells recovered determined. Each population, together with unfractionated normal and immune (regressor) cells, was then divided into two and one half treatedwithBranti-O and complement, the other with medium and complement. Equal numbers of viable cells recovered after such treatment were then tested in vitro for stimulation with MSV antigens (2 x 106 cells per culture) or in vivo for their ability to protect irradiated MSV inoculated mice (4 x 106 cells per mouse). The data for this experiment are shown in Table III .
It is clear from this table that the activity seen with both in vivo and in vitro assays from small regressor cells, or from unfractionated regressor cells, was completely abolished by treatment with Br anti-C and complement. It seemed that all of the large regressor cells responding in vitro were also T lymphocytes. However, while Br anti-C and complement reduced the in vivo activity of large regressor cells, it was not clear that the activity was wholly abolished. It may be that the large T lymphoctyes were less sensitive to Br anti-C than small T cells (though the data from the in vitro assay did not support this notion). An alternative explanation was that another cell type, sedimenting in this region of the gradient, was also active in the in vivo assay but not in the in vitro assay. Perhaps this cell is an " activated macrophage ", suggested by other workers as (Evans and Alexander, 1972) .
Ability of progressor spleen cells to block protection by regressor spleen cells
We have presented evidence to suggest that the cells immune to MSV as detected by in vitro stimulation assay may also be the cells important in protecting sublethally irradiated mice given MSV from the lethal effects of progressively growing sarcomata. However, while we could easily demonstrate the presence of an auxiliary cell type in progressor animals, which blocked the observed in vitro immunity seen from the spleens or lymph nodes of these animals (Gorczynski, 1974c) there was no obvious role for such a cell type when we used the in vivo assay described (Table II and the Fig.) . While it was certainly possible that the explanation lay in the fact that the in vitro assay was open to many non-physiological artefacts, an alternative explanation was that after adoptive transfer into these sublethally irradiated recipients there was, perhaps for a variety of reasons, a reduced likelihood of the cell-to-cell interaction needed to witness the suppression seen in vitro. In order to examine whether the in vitro suppressor cells were related physiologically to the tumour growth status of the host mice (such cells were found only in animals with progressively growing tumours), we investigated the effect of adding a large excess of progressor spleen cells to small numbers of regressor cells before adoptive transfer into irradiated recipients (given MSV). Since unfractionated progressor cells could themselves protect these animals (Table II and Fig.) and since, at least in regressor animals, the protection could be abolished by treatment with Br anti-d and complement, we pretreated the cells added to the regressor cells with Br anti-0 and complement. In control groups Br anti-6 treated normal or regressor spleen cells were also added to small numbers of untreated regressor cells to investigate their ability to affect the protection afforded by untreated regressor cells.
Spleen cells were taken from mice given MSV 10 or 24 days beforehand, as well as from non-infected mice (age matched to the 24-day post-MSV mice); 8 mice of each type were used to prepare the 3 pools of cells. 8 X 108 cells of each population were treated with Br anti-O and complement, as described in the Materials and Methods section; 50 X 106 of each of the treated cell suspensions were then injected, alone or in combination with 5 X 106 regressor spleen cells, into irradiated mice inoculated with MSV. Con- No. of micee with tumours 0/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
Time of peakd Time of tumoure tumour volume regression 11(2-2) 9(2*6) 11(2-0) 17 11(1 8) 16 12(2-1) 9(2*0) 1 1(1 * 9) 11(2-4) Survival atf 25 days 6/6 0/6 0/6 6/6 6/6 0/6 0/6 1/6 6/6 3/6 6/6 trol groups investigated the protection afforded by 10 x 106 untreated cells of each type. The data for this experiment are shown in Table IV . As described in Table II, (Gorczynski, 1974c) . Analysis of the sensitivity of these cells (active in vivo) to anti-Ig serum has not proved possible in view of the greater number of suppressor cells needed to see activity in vivo (above and Gorezynski, 1 974c) and the overlap with " active cells " in the gradient separation used.
DISCUSSION
Previous papers in this series have shown that the spleens of MSV regressor animals contain T lymphocytes capable of: (i) protecting sublethally irradiated mice from the now lethal effect of MSV inoculation (Gorczynski, 1974a; Fefer, 1969) ; (ii) responding to MSV antigens in vitro with enhanced DNA and protein synthesis (Gorezynski, 1974b) .
Other workers have suggested that in vitro assays in this system detect T cell (Leclerc, Gomard and Levy, 1972) , B cell (Lamon et al., 1972) or macrophage (Owen and Seeger, 1973 ) mediated immunity. Previous work, studying the ability of cells and/or serum to protect sublethally irradiated animals from progressive tumour growth (with ultimate death of the host), suggested that both cell mediated and humoral immunity may be important (Fefer et al., 1968; Fefer, 1969; Pearson, Redman and Bass, 1973) . Subsequent work supported both of these findings (Gorczynski, 1 974a), though it was concluded that when limiting cell numbers were injected the role of antiviral antibody in protection was greatly reduced. Indeed, sera from all of the animals used in the course of these studies were examined throughout for anti-viral antibody by Dr R. A. Knight, with consistently negative results. Hellstrom (1969, 1970) have suggested that during the progressive phase of growth of the MSV induced sarcoma, anti-tumour immunity in vivo is blocked by factors in the serum, perhaps antigen-antibody complexes (Sjogren et al., 1971) . The suggestion was made that these blocking factors themselves provided the environment which allowed tumour growth in the face of anti-tumour directed immunity (Halliday, 1972; Hellstrom, 1969,1970; Baldwin, Price and Robins, 1972) . In an analogous fashion, it has been suggested that a cell which blocks T lymphocyte activity in a nonspecific manner may be in some way be responsible for tumour progression (Gorczynski, 1974c) . Both hypotheses would gain much in credibility if their physiological importance could be demonstrated in a more direct fashion.
We have noted in this report that, unlike their inability to respond using in vitro assays, cells from progressor animals were fully capable of protecting sublethally irradiated mice inoculated with MSV (Table II) . Vhile this was an anomalous finding with respect to the in vitro data, more detailed examination of the reactive cells in progressor and regressor animals using the in vitro and in vivo assays ruled out the possibility that the two assays were not related. The cells active in each had similar sedimentation characteristics (Fig.) , and similar sensitivities to Br anti-O serum and complement (Table III) . The latter observation was tempered by the consistent finding that large cells in the spleens of MSV regressor animals were inactive after Br anti-6 treatment using the in vitro assay, but retained appreciable activity in vivo (Table III) . This is perhaps best explained by suggesting that sensitized antigen-specific T lymphocytes may activate non-T cells (macrophages) to kill tumour cells (Evans and Alexander, 1972) , a possibility already suggested for the MSV system by the work of Owen and Seeger (1973) and Houchens et al. (1973) .
If similar effector cell types are responsible for activity in vitro and in vivo, the anomalous behaviour of progressor spleen cells in vitro may be due to an inhibition of activity which has little physiological significance, whether the inhibition is specific Hellstrom, 1969, 1970; Halliday, 1972) or nonspecific (Gorczynski, 1974c) . However, the data of Table IV suggest an alternative explanation, namely, that in the adoptive transfer system used to investigate immunity in vivo, there is less likelihood of the cell contact necessary for inhibition, and this likelihood is increased by merely increasing the number of " suppressor " cells inoculated.
In a previous report, non-antigen specific blocking of T cell mediated immunity was reported in MSV progressor mice (Gorczynski, 1974c) . Blocking by serum factors is of an antigen specific type (Hellstr6m and Hellstrom, 1969, 1970; Halliday, 1972) . It is quite feasible that both types of suppression could be encompassed within the same model, perhaps even being caused by similar molecules . The main difference between the two types of suppression would then perhaps be caused by the concentration of blocking factors present. At present no evidence allows us to make conclusive answers to such questions. Indeed, there are as yet no definitive data to show that " blocking " in vivo is of a specific or nonspecific nature, or that it is related to the " blocking " seen in vitro. Current work is engaged in examining the relationship between specific and nonspecific suppression in vitro and in vtvo.
